Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Leap Therapeutics, Inc. (LPTX)

1.38   -0.02 (-1.43%) 09-29 16:00
Open: 1.45 Pre. Close: 1.4
High: 1.45 Low: 1.35
Volume: 119,548 Market Cap: 35(M)

Technical analysis

as of: 2023-09-29 4:28:49 PM
Short-term rate:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Mid-term rate:       
Target: Six months: 2.32     One year: 2.83
Support: Support1: 1.26    Support2: 1.05
Resistance: Resistance1: 1.98    Resistance2: 2.43
Pivot: 1.5
Moving Average: MA(5): 1.37     MA(20): 1.64
MA(100): 3.66     MA(250): 4.81
MACD: MACD(12,26): -0.3     Signal(9): -0.3
Stochastic oscillator: %K(14,3): 16.5     %D(3): 13.3
RSI: RSI(14): 28.1
52-week: High: 10.19  Low: 1.26
Average Vol(K): 3-Month: 253 (K)  10-Days: 134 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ LPTX ] has closed above bottom band by 32.5%. Bollinger Bands are 70% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 55 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.45 - 1.46 1.46 - 1.47
Low: 1.33 - 1.34 1.34 - 1.35
Close: 1.37 - 1.38 1.38 - 1.39

Company Description

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Headline News

Tue, 05 Sep 2023
Leap Therapeutics to Participate at Upcoming Investor Conferences - Yahoo Finance

Wed, 16 Aug 2023
Is it Time to Dump Leap Therapeutics Inc (LPTX) Stock After it Has Risen 7.62% in a Week? - InvestorsObserver

Wed, 12 Jul 2023
Leap Therapeutics Announces Initiation of Randomized Controlled ... - PR Newswire

Tue, 20 Jun 2023
Leap Therapeutics Announces Reverse Stock Split - PR Newswire

Thu, 25 May 2023
Leap Therapeutics to Present Updated Data from Part A of the ... - PR Newswire

Mon, 15 May 2023
Leap Therapeutics Reports First Quarter 2023 Financial Results - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 26 (M)
Shares Float 25 (M)
% Held by Insiders 3.8 (%)
% Held by Institutions 23.3 (%)
Shares Short 672 (K)
Shares Short P.Month 733 (K)

Stock Financials

EPS -5.99
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.28
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -55.7
Return on Equity (ttm) -98.6
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -3.31
Qtrly Earnings Growth 0
Operating Cash Flow -48 (M)
Levered Free Cash Flow -49 (M)

Stock Valuations

PE Ratio -0.24
PEG Ratio 0.1
Price to Book value 0.41
Price to Sales 0
Price to Cash Flow -0.74

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.